Stock Fundamentals

Company Information

Company Name
C4 Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US12529R1077
CIK: 0001662579
CUSIP: 12529R107
Currency: USD
Full Time Employees: 104
Phone: 617 231 0700
Fiscal Year End: December
IPO Date: Oct 02, 2020
Description:

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Address:

490 Arsenal Way, Watertown, MA, United States, 02472

Directors & Officers

Name Title Year Born
Mr. Andrew J. Hirsch M.B.A. CEO, President & Director 1971
Dr. Kenneth C. Anderson M.D., Ph.D. Co-Founder, Independent Director & Member of Scientific Advisory Board 1951
Ms. Kendra R. Adams Chief Financial Officer and Head of Corporate Affairs & Treasurer 1977
Dr. Leonard M. J. Reyno M.D. Chief Medical Officer 1962
Dr. Nathanael S. Gray Ph.D. Co-Founder & Member of Scientific Advisory Board NA
Mr. Mark Mossler Chief Accounting Officer 1974
Ms. Paige Mahaney Ph.D. Chief Scientific Officer 1970
Ms. Courtney Solberg Senior Manager of Investor Relations NA
Ms. Kelly A. Schick Chief People Officer 1980
Dr. Isabel Chiu Ph.D. Senior Vice President of Strategic Alliances & Business Development NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Jan 16, 2026 Leonard Reyno N/A Sale 10.00K $2.22 $22.20K

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Morgan Stanley - Brokerage Accounts 9.07M Mar 31, 2026 8.23% $0.00 1.01%
RA Capital Management, LLC 8.00M Mar 31, 2026 7.26% $0.22 0.00%
Bain Capital Life Sciences Investors, LLC 7.17M Mar 31, 2026 6.51% $1.70 0.00%
Lynx1 Capital Management, LP 7.00M Mar 31, 2026 6.35% $2.91 -1.40%
Vanguard Group Inc 4.38M Dec 31, 2025 3.98% $0.00 37.23%
Soleus Capital Management, L.P. 3.80M Mar 31, 2026 3.45% $0.41 0.00%
JPMorgan Chase & Co 3.22M Mar 31, 2026 2.93% $0.00 54,114.53%
Two Sigma Investments LLC 3.04M Mar 31, 2026 2.76% $0.01 101.09%
Wasatch Advisors LP 2.96M Mar 31, 2026 2.69% $0.05 -31.83%
Citadel Advisors Llc 2.51M Mar 31, 2026 2.28% $0.00 460.73%
Renaissance Technologies Corp 2.46M Mar 31, 2026 2.23% $0.01 53.62%
The Goldman Sachs Group Inc 2.39M Mar 31, 2026 2.17% $0.00 119.22%
Bank of America Corp 2.36M Mar 31, 2026 2.14% $0.00 -1.19%
Squadron Capital Management LLC 2.25M Mar 31, 2026 2.04% $2.17 0.00%
BlackRock Inc 2.05M Mar 31, 2026 1.86% $0.00 4.00%
SILVERARC CAPITAL MANAGEMENT, LLC 1.91M Mar 31, 2026 1.74% $0.51 -4.13%
Acadian Asset Management LLC 1.89M Mar 31, 2026 1.72% $0.01 0.00%
Millennium Management LLC 1.39M Mar 31, 2026 1.26% $0.00 17.19%
Susquehanna International Group, LLP 1.29M Mar 31, 2026 1.17% $0.00 -27.53%
Jane Street Group LLC 1.25M Mar 31, 2026 1.13% $0.00 42.54%

Shares Statistics

Shares Outstanding: 110.57M
Shares Float: 79.64M
% Insiders: 112.50%
% Institutions: 8,516.00%
Short % Float: 19.35%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Total Stock Mkt Idx Inv 2.89M 2.63% ▲ 0.00% Apr 30, 2026
2 Wasatch Ultra Growth 2.65M 2.40% ▼ 6.25% Mar 31, 2026
3 Biotech Growth Ord 1.27M 1.16% ▲ 393.42% Feb 28, 2026
4 Vanguard Institutional Extnd Mkt Idx Tr 882.93K 0.80% ▲ 0.00% Apr 30, 2026
5 iShares Biotechnology ETF 599.98K 0.54% ▲ 0.64% Apr 30, 2026
6 Fidelity Enhanced Small Cap Core ETF 580.25K 0.53% ▼ 1.15% Apr 30, 2026
7 JNL Multi-Manager Small Cap Value I 471.63K 0.43% ▲ 0.00% Mar 31, 2026
8 Schwab US Small-Cap ETF™ 384.04K 0.35% ▼ 0.01% Apr 30, 2026
9 Fidelity Extended Market Index 345.89K 0.31% ▲ 6.05% Mar 31, 2026
10 Dimensional US Small Cap ETF 321.95K 0.29% ▲ 0.00% Apr 30, 2026

Valuation Metrics

Enterprise Value: $307.06M
Trailing P/E: 0.00
Forward P/E: 0.00

Financial Highlights

Market Cap: $451.11M
EBITDA: $-101.20M
Book Value: $2.25
Earnings/Share: $-1.10
Profit Margin: -297.76%
Operating Margin: -451.64%
ROA (TTM): -19.88%
ROE (TTM): -48.35%
Revenue (TTM): $34.86M
Revenue/Share (TTM): $0.36
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -15.00%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 7.81x 0.02x 0.29x N/A -0.06x
2024-12-31 5.71x 0.03x 0.38x N/A -0.06x
2023-12-31 6.34x 0.02x 0.35x -101.26x -0.04x
2022-12-31 6.46x 0.06x 0.33x -58.45x -0.13x
2021-12-31 6.36x 0.03x 0.23x -38.29x -0.15x
2020-12-31 8.69x 0.04x 0.30x -49.19x -0.19x
2019-12-31 2.88x -0.01x 1.95x -16.44x -0.03x
2018-12-31 5.16x -0.01x 1.54x N/A -0.05x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about CCCC.US!